{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:41Z","timestamp":1772496041674,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,2]]},"DOI":"10.7759\/cureus.104567","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T23:32:08Z","timestamp":1772494328000},"source":"Crossref","is-referenced-by-count":0,"title":["Emerging Role of Dual Glucagon-Like Peptide-1 (GLP-1)\/Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonists in Cardiovascular Prevention"],"prefix":"10.7759","author":[{"given":"Nicolle","family":"Contreras Figueroa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maynor Jose","family":"Lopez Mendoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asdrubal","family":"Ulloa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeilyn","family":"Jiron Vindas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Antonieta","family":"Salazar Estrada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jennifer","family":"Valle Mena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14186678","article-title":"Rethinking the diabetes-cardiovascular disease continuum: toward integrated care","volume":"14","author":"Caturano A","year":"2025","unstructured":"Caturano A, Morciano C, Zieli\u0144ska K, Russo V, Perrone MA, Berra CC, Conte C. Rethinking the diabetes-cardiovascular disease continuum: toward integrated care. J Clin Med. 2025, 14:6678. 10.3390\/jcm14186678","journal-title":"J Clin Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14196758","article-title":"GLP-1 agonists in cardiovascular diseases: mechanisms, clinical evidence, and emerging therapies","volume":"14","author":"Yang HM","year":"2025","unstructured":"Yang HM. GLP-1 agonists in cardiovascular diseases: mechanisms, clinical evidence, and emerging therapies. J Clin Med. 2025, 14:6758. 10.3390\/jcm14196758","journal-title":"J Clin Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2024.102489","article-title":"Tirzepatide: A novel cardiovascular protective agent in type 2 diabetes mellitus and obesity","volume":"49","author":"Sardar MB","year":"2024","unstructured":"Sardar MB, Nadeem ZA, Babar M. Tirzepatide: A novel cardiovascular protective agent in type 2 diabetes mellitus and obesity. Curr Probl Cardiol. 2024, 49:102489. 10.1016\/j.cpcardiol.2024.102489","journal-title":"Curr Probl Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-24-0046","article-title":"GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms","volume":"263","author":"Mullur N","year":"2024","unstructured":"Mullur N, Morissette A, Morrow NM, Mulvihill EE. GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms. J Endocrinol. 2024, 263:10.1530\/JOE-24-0046","journal-title":"J Endocrinol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-05973-w","article-title":"Incretins and cardiovascular disease: to the heart of type 2 diabetes?","volume":"66","author":"Solini A","year":"2023","unstructured":"Solini A, Tric\u00f2 D, Del Prato S. Incretins and cardiovascular disease: to the heart of type 2 diabetes?. Diabetologia. 2023, 66:1820-31. 10.1007\/s00125-023-05973-w","journal-title":"Diabetologia"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01412-5","article-title":"The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect","volume":"20","author":"Fisman EZ","year":"2021","unstructured":"Fisman EZ, Tenenbaum A. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Cardiovasc Diabetol. 2021, 20:225. 10.1186\/s12933-021-01412-5","journal-title":"Cardiovasc Diabetol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf110","article-title":"GLP-1-based therapeutics for cardiorenal protection in metabolic diseases","volume":"41","author":"Apperloo EM","year":"2026","unstructured":"Apperloo EM, Heerspink HJ, van Raalte DH, Muskiet MH. GLP-1-based therapeutics for cardiorenal protection in metabolic diseases. Nephrol Dial Transplant. 2026, 41:207-19. 10.1093\/ndt\/gfaf110","journal-title":"Nephrol Dial Transplant"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15462","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits-the role of the GLP-1 receptor","volume":"179","author":"Helmst\u00e4dter J","year":"2022","unstructured":"Helmst\u00e4dter J, Keppeler K, K\u00fcster L, M\u00fcnzel T, Daiber A, Steven S. Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits-the role of the GLP-1 receptor. Br J Pharmacol. 2022, 179:659-76. 10.1111\/bph.15462","journal-title":"Br J Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/biology11020288","article-title":"Gastrointestinal incretins-glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) beyond pleiotropic physiological effects are involved in pathophysiology of atherosclerosis and coronary artery disease-state of the art","volume":"11","author":"Jonik S","year":"2022","unstructured":"Jonik S, Marchel M, Grabowski M, Opolski G, Mazurek T. Gastrointestinal incretins-glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) beyond pleiotropic physiological effects are involved in pathophysiology of atherosclerosis and coronary artery disease-state of the art. Biology (Basel). 2022, 11:288. 10.3390\/biology11020288","journal-title":"Biology (Basel)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02319-7","article-title":"Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide","volume":"23","author":"Taktaz F","year":"2024","unstructured":"Taktaz F, Fontanella RA, Scisciola L, et al.. Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide. Cardiovasc Diabetol. 2024, 23:242. 10.1186\/s12933-024-02319-7","journal-title":"Cardiovasc Diabetol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-025-01784-x","article-title":"Can dual incretin receptor agonists exert better cardiovascular protection than selective GLP-1 receptor agonists? Highlights from surpass-CVOT","volume":"16","author":"Fadini GP","year":"2025","unstructured":"Fadini GP. Can dual incretin receptor agonists exert better cardiovascular protection than selective GLP-1 receptor agonists? Highlights from surpass-CVOT. Diabetes Ther. 2025, 16:1893-8. 10.1007\/s13300-025-01784-x","journal-title":"Diabetes Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15318","article-title":"Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis","volume":"26","author":"Hankosky ER","year":"2024","unstructured":"Hankosky ER, Wang H, Neff LM, et al.. Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis. Diabetes Obes Metab. 2024, 26:319-28. 10.1111\/dom.15318","journal-title":"Diabetes Obes Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1042\/CS20220404","article-title":"Depot-specific adipose tissue modulation by SGLT2 inhibitors and GLP1 agonists mediates their cardioprotective effects in metabolic disease","volume":"136","author":"Bakkar NZ","year":"2022","unstructured":"Bakkar NZ, AlZaim I, El-Yazbi AF. Depot-specific adipose tissue modulation by SGLT2 inhibitors and GLP1 agonists mediates their cardioprotective effects in metabolic disease. Clin Sci (Lond). 2022, 136:1631-51. 10.1042\/CS20220404","journal-title":"Clin Sci (Lond)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14553","article-title":"The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: a post hoc analysis","volume":"24","author":"Wilson JM","year":"2022","unstructured":"Wilson JM, Lin Y, Luo MJ, et al.. The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: a post hoc analysis. Diabetes Obes Metab. 2022, 24:148-53. 10.1111\/dom.14553","journal-title":"Diabetes Obes Metab"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232314631","article-title":"Tirzepatide: a systematic update","volume":"23","author":"Forzano I","year":"2022","unstructured":"Forzano I, Varzideh F, Avvisato R, Jankauskas SS, Mone P, Santulli G. Tirzepatide: a systematic update. Int J Mol Sci. 2022, 23:14631. 10.3390\/ijms232314631","journal-title":"Int J Mol Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16106","article-title":"Why does GLP-1 agonist combined with GIP and\/or GCG agonist have greater weight loss effect than GLP-1 agonist alone in obese adults without type 2 diabetes?","volume":"27","author":"Jiang Y","year":"2025","unstructured":"Jiang Y, Zhu H, Gong F. Why does GLP-1 agonist combined with GIP and\/or GCG agonist have greater weight loss effect than GLP-1 agonist alone in obese adults without type 2 diabetes?. Diabetes Obes Metab. 2025, 27:1079-95. 10.1111\/dom.16106","journal-title":"Diabetes Obes Metab"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16203","article-title":"The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP-1\/GIP receptor agonist (BGM0504) in healthy volunteers: a dose-escalation Phase I study","volume":"27","author":"Fan Y","year":"2025","unstructured":"Fan Y, Yuan J, Dong L, et al.. The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP-1\/GIP receptor agonist (BGM0504) in healthy volunteers: a dose-escalation Phase I study. Diabetes Obes Metab. 2025, 27:2110-9. 10.1111\/dom.16203","journal-title":"Diabetes Obes Metab"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/23969873241234238","article-title":"Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP\/GLP-1 receptor agonist tirzepatide for type 2 diabetes: a systematic review and meta-analysis","volume":"9","author":"Stefanou MI","year":"2024","unstructured":"Stefanou MI, Theodorou A, Malhotra K, et al.. Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP\/GLP-1 receptor agonist tirzepatide for type 2 diabetes: a systematic review and meta-analysis. Eur Stroke J. 2024, 9:530-9. 10.1177\/23969873241234238","journal-title":"Eur Stroke J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00981-0","article-title":"The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: The SURPASS clinical trials","volume":"12","author":"Min T","year":"2021","unstructured":"Min T, Bain SC. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: The SURPASS clinical trials. Diabetes Ther. 2021, 12:143-57. 10.1007\/s13300-020-00981-0","journal-title":"Diabetes Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis","volume":"28","author":"Sattar N","year":"2022","unstructured":"Sattar N, McGuire DK, Pavo I, Weerakkody GJ, Nishiyama H, Wiese RJ, Zoungas S. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022, 28:591-8. 10.1038\/s41591-022-01707-4","journal-title":"Nat Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000001066","article-title":"Glucagon-like peptide-1 receptor agonists to improve cardiorenal outcomes: data from FLOW and beyond","volume":"34","author":"Faruque L","year":"2025","unstructured":"Faruque L, Yau K, Cherney DZ. Glucagon-like peptide-1 receptor agonists to improve cardiorenal outcomes: data from FLOW and beyond. Curr Opin Nephrol Hypertens. 2025, 34:232-40. 10.1097\/MNH.0000000000001066","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1121387","article-title":"A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?","volume":"14","author":"Meng Z","year":"2023","unstructured":"Meng Z, Yang M, Wen H, Zhou S, Xiong C, Wang Y. A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?. Front Endocrinol (Lausanne). 2023, 14:1121387. 10.3389\/fendo.2023.1121387","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2337\/db23-75-lb","article-title":"75-LB: CT-388, a novel once-weekly dual GLP-1 and GIP receptor modulator, is safe, well-tolerated, and produces more than 8% weight loss in four weeks in overweight and obese adults","volume":"72","author":"Chakravarthy M","year":"2023","unstructured":"Chakravarthy M, Arg\u00fcelles F, Sun A, et al.. 75-LB: CT-388, a novel once-weekly dual GLP-1 and GIP receptor modulator, is safe, well-tolerated, and produces more than 8% weight loss in four weeks in overweight and obese adults. Diabetes. 2023, 72:75-LB. 10.2337\/db23-75-lb","journal-title":"Diabetes"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02500-y","article-title":"Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives","volume":"23","author":"Sawami K","year":"2024","unstructured":"Sawami K, Tanaka A, Node K. Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives. Cardiovasc Diabetol. 2024, 23:410. 10.1186\/s12933-024-02500-y","journal-title":"Cardiovasc Diabetol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16078","article-title":"One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with SGLT2i or GLP1RA","volume":"27","author":"Zhang M","year":"2025","unstructured":"Zhang M, Lin C, Cai X, et al.. One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with SGLT2i or GLP1RA. Diabetes Obes Metab. 2025, 27:806-15. 10.1111\/dom.16078","journal-title":"Diabetes Obes Metab"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000837324.54362.4b","article-title":"'Which one should I choose, a GLP-1Ra or a SGLT2 inhibitor? Or maybe both?' A pooled analysis of cardiovascular outcome trials","volume":"40","author":"Patoulias D","year":"2022","unstructured":"Patoulias D, Katsimardou A, Toumpourleka M, et al.. 'Which one should I choose, a GLP-1Ra or a SGLT2 inhibitor? Or maybe both?' A pooled analysis of cardiovascular outcome trials. J Hypertens. 2022, 40:187-98. 10.1097\/01.hjh.0000837324.54362.4b","journal-title":"J Hypertens"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae666.2775","article-title":"Cardiovascular prevention with GLP1 agonists in high or very-high cardiovascular risk irrespective of diabetes","volume":"45","author":"Del-Cuerpo-Salinas N","year":"2024","unstructured":"Del-Cuerpo-Salinas N, Cazorla-Morallon D, Perez-Ferrandiz A, et al.. Cardiovascular prevention with GLP1 agonists in high or very-high cardiovascular risk irrespective of diabetes. Eur Heart J. 2024, 45:ehae666.2775. 10.1093\/eurheartj\/ehae666.2775","journal-title":"Eur Heart J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/469674-emerging-role-of-dual-glucagon-like-peptide-1-glp-1glucose-dependent-insulinotropic-polypeptide-gip-receptor-agonists-in-cardiovascular-prevention","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T23:32:10Z","timestamp":1772494330000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/469674-emerging-role-of-dual-glucagon-like-peptide-1-glp-1glucose-dependent-insulinotropic-polypeptide-gip-receptor-agonists-in-cardiovascular-prevention"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.104567","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,2]]}}}